advertisement

WGA Rescources

Monja-Alarcón N 10

Showing records 1 to 10 | Display all abstracts from Monja-Alarcón N

99339 Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Buenasmañanas-Maeso M; Buenasmañanas-Maeso M
Clinical Ophthalmology 2022; 16: 935-946
98994 Does mitomycin-C concentration have any influence on XEN45 gel stent outcomes in a real-world setting?
Monja-Alarcón N; Monja-Alarcón N; Perucho-Martínez S
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 2649-2661
99339 Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Perucho-Martínez S
Clinical Ophthalmology 2022; 16: 935-946
98994 Does mitomycin-C concentration have any influence on XEN45 gel stent outcomes in a real-world setting?
Perucho-Martínez S
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 2649-2661
99339 Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Perucho-Martínez S
Clinical Ophthalmology 2022; 16: 935-946
98994 Does mitomycin-C concentration have any influence on XEN45 gel stent outcomes in a real-world setting?
Buenasmañanas-Maeso M
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 2649-2661
99339 Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Monja-Alarcón N
Clinical Ophthalmology 2022; 16: 935-946
98994 Does mitomycin-C concentration have any influence on XEN45 gel stent outcomes in a real-world setting?
Buenasmañanas-Maeso M
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 2649-2661
99339 Impact of Primary Needling on the XEN Implant Clinical Outcomes: A Real-Life Retrospective Study
Monja-Alarcón N; Toledano-Fernández N
Clinical Ophthalmology 2022; 16: 935-946
98994 Does mitomycin-C concentration have any influence on XEN45 gel stent outcomes in a real-world setting?
Toledano-Fernández N
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 2649-2661

Issue 22-4

Change Issue


advertisement

Oculus